Successful treatment of secukinumab in severe plaque psoriasis

Psoriasis is a persistent, chronic condition that manifests on the skin, joints, and other visible places that compromises the quality of life. The vast understanding of the pathophysiology of psoriasis has led to a rise in the use of biological therapy in treating psoriasis in recent years. A 48-year-old woman with severe plaque psoriasis was previously treated with methotrexate and phototherapy for 3 months, however, the treatment showed no significant improvement. The patient was then treated with a biological agent, namely secukinumab, with a dose of 150 mg weekly for 5 weeks followed by one dose a month later. The symptoms were improved considerably after 10 weeks of observation, which indicated by the decrease in Psoriasis Area Severity Index (PASI) score and the Dermatology Life Quality Index (DLQI) score. There was no significant side effect during the observation. This case showed that secukinumab therapy at a dose of 150 mg can successfully treat severe plaque psoriasis patient.